These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10420076)

  • 1. Adenosine 5'-diphosphate-induced platelet aggregation in uremia shows resistance to inhibition by the novel nitric oxide donor GEA 3175 but not by S-nitroso-N-acetylpenicillamine.
    Whiss PA; Larsson R
    Haemostasis; 1998; 28(5):260-7. PubMed ID: 10420076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro.
    Persson K; Whiss PA; Nyhlén K; Jacobsson-Strier M; Glindell M; Andersson RG
    Eur J Pharmacol; 2000 Oct; 406(1):15-23. PubMed ID: 11011027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
    Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
    Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide-donating properties of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives.
    Kankaanranta H; Rydell E; Petersson AS; Holm P; Moilanen E; Corell T; Karup G; Vuorinen P; Pedersen SB; Wennmalm A; Metsä-Ketelä T
    Br J Pharmacol; 1996 Feb; 117(3):401-406. PubMed ID: 8821526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical releasing properties of nitric oxide donors GEA 3162, SIN-1 and S-nitroso-N-acetylpenicillamine.
    Holm P; Kankaanranta H; Metsä-Ketelä T; Moilanen E
    Eur J Pharmacol; 1998 Apr; 346(1):97-102. PubMed ID: 9617758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human lymphocyte proliferation by nitric oxide-releasing oxatriazole derivatives.
    Kosonen O; Kankaanranta H; Vuorinen P; Moilanen E
    Eur J Pharmacol; 1997 Oct; 337(1):55-61. PubMed ID: 9389381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives on vascular smooth muscle cell mitogenesis and proliferation in vitro.
    Lähteenmäki T; Sievi E; Vapaatalo H
    Br J Pharmacol; 1998 Sep; 125(2):402-8. PubMed ID: 9786515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide and prostacyclin inhibit fetal platelet aggregation: a response similar to that observed in adults.
    Varela AF; Runge A; Ignarro LJ; Chaudhuri G
    Am J Obstet Gynecol; 1992 Dec; 167(6):1599-604. PubMed ID: 1471673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine on human platelets.
    Salas E; Moro MA; Askew S; Hodson HF; Butler AR; Radomski MW; Moncada S
    Br J Pharmacol; 1994 Aug; 112(4):1071-6. PubMed ID: 7524991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-Nitroso-N-acetylpenicillamine (SNAP) during hemorrhagic shock improves mortality as a result of recovery from vascular hyporeactivity.
    Sato S; Suzuki A; Nakajima Y; Iwamoto T; Bito H; Miyabe M
    Anesth Analg; 2000 Feb; 90(2):362-8. PubMed ID: 10648322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide.
    Klinge JM; Topf HG; Trusen B; Rauh M; Rascher W; Dötsch J
    Crit Care Med; 2003 Jul; 31(7):2010-4. PubMed ID: 12847397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil.
    Berkels R; Klotz T; Sticht G; Englemann U; Klaus W
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):413-21. PubMed ID: 11300654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators.
    Salvemini D; Currie MG; Mollace V
    J Clin Invest; 1996 Jun; 97(11):2562-8. PubMed ID: 8647949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of relaxations of bovine isolated bronchioles by the nitric oxide donor, GEA 3175.
    Hernández M; Elmedal B; Mulvany MJ; Simonsen U
    Br J Pharmacol; 1998 Mar; 123(5):895-905. PubMed ID: 9535018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms.
    Sogo N; Magid KS; Shaw CA; Webb DJ; Megson IL
    Biochem Biophys Res Commun; 2000 Dec; 279(2):412-9. PubMed ID: 11118301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition by nitric oxide-releasing compounds of prostacyclin production in human endothelial cells.
    Kosonen O; Kankaanranta H; Malo-Ranta U; Ristimäki A; Moilanen E
    Br J Pharmacol; 1998 Sep; 125(2):247-54. PubMed ID: 9786495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.
    Gordge MP; Hothersall JS; Noronha-Dutra AA
    Br J Pharmacol; 1998 May; 124(1):141-8. PubMed ID: 9630353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide and platelet energy metabolism.
    Tomasiak M; Stelmach H; Rusak T; Wysocka J
    Acta Biochim Pol; 2004; 51(3):789-803. PubMed ID: 15448739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel family of S-nitrosothiols: chemical synthesis and biological actions.
    Al-Sa'doni HH; Khan IY; Poston L; Fisher I; Ferro A
    Nitric Oxide; 2000 Dec; 4(6):550-60. PubMed ID: 11139363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic inhibition of thrombin-induced platelet aggregation by the novel nitric oxide-donor GEA 3175 and adenosine.
    Grenegård M; Gustafsson MC; Andersson RG; Bengtsson T
    Br J Pharmacol; 1996 Aug; 118(8):2140-4. PubMed ID: 8864553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.